跳至主要内容
临床试验/NCT00533065
NCT00533065已完成不适用

Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone

Ludwig Boltzmann Gesellschaft2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2007年9月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
2
主要终点
Serum IGF1

研究概览

简要总结

The planned study has two purposes:

  1. It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year.
  2. The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
70 Years 至 80 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged between 70 and 80 years

排除标准

  • Cardiac arrhythmias (sick sinus syndrome, AV block, sino-atrial block),
  • Treatment with beta-blockers, NSAIDs or cholinergic agonists,
  • Known hypersensitivity to donepezil hydrochloride, piperidine derivatives or to any excipients used in the formulation,
  • Gastric and duodenal ulcer,
  • Severe renal and hepatic impairment,
  • Urinary congestion (prostatic hypertrophy),
  • Obstructive pulmonary disease (bronchial asthma);

结局指标

主要结局

Serum IGF1

时间窗: one year

次要结局

  • Growth hormone, body composition variables(one year)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验